(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

California Gov. Gavin Newsom, a leading Democratic critic of President Donald Trump, says he'll consider running for the ...

Key points A 40-year-old woman presented to her family physician with a new subcutaneous mass in the right lower quadrant of her abdomen, along with nonspecific systemic symptoms, including occasional ...

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price ...

Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French drugmaker ...

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company recently completed ...

Veterinary teams enhance feline diabetes management through personalized care, effective communication, and evolving treatment options for improved quality of life.

The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...